1,107 research outputs found

    Dynamical properties of quasiparticles in a tunable Kekul\'{e} graphene superlattice

    Full text link
    We investigate the dynamical properties of quasiparticles in graphene superlattices with three typical Kekul\'{e} distortions (i.e., Kekul\'{e}-O, Kekul\'{e}-Y and Kekul\'{e}-M). On the one hand, we numerically show the visualized evolution process of Kekul\'{e} quasiparticles; while on the other hand, we analytically obtain the centroid trajectory of the quasiparticles, and both of them agree well with each other. The results reveal that the relativistic Zitterbewegung (ZB) phenomenon occurs in the Kekul\'{e} systems. Furthermore, through analyzing the frequency of ZB, we unveil the one-to-one relationship between ZB and Kekul\'{e} textures, i.e., the ZB frequenies of Kekul\'{e}-O, Kekul\'{e}-Y and Kekul\'{e}-M quasiparticles feature single, double and six frequencies, respectively. Finally, we propose a scheme to distinguish among different Kekul\'{e} textures from the dynamical perspective. The predictions in this paper are expected to be experimentally verified in the near future, so as to facilitate further research of Kekul\'{e} structures in solid materials or artificial systems

    Network meta-analysis of the efficacy and safety of monoclonal antibodies and traditional conventional dichotomous agents for chronic obstructive pulmonary disease

    Get PDF
    IntroductionMonoclonal antibodies (mAbs) against cytokines and chemokines or their receptors promise to be a potential therapeutic option to address chronic obstructive pulmonary disease (COPD). We aim to provide a comprehensive literature review of the improvement in FEV1 and safety when comparing mAbs with conventional dichotomous agents.MethodsWe systematically searched 3 electronic databases (PubMed, EMBASE, and CENTRAL) up to August 1, 2023 to collect eligible randomized controlled trials (RCTs). A frequentist network meta-analysis using a random-effects model was deployed to calculate mean differences (MD) for FEV1, relative risk (RR) of treatment-emergent adverse events (TEAEs), and estimate the surface under cumulative rankings (SUCRA). A higher SUCRA indicates a better outcome.ResultsThis study included 23 RCTs involving a total of 20,853 patients. Overall, except for Dupilumab, mAbs did not significantly improve FEV1 compared to traditional conventional dichotomous agents. Among all the interventions included, Aclidinium bromide/Formoterol (AB/FF) (SUCRA 97.7%) ranked highest, followed by Umeclidinium/vilanterol (UMEC/VI) (SUCRA 93.5%), and Glycopyrrolate Formoterol Fumarate (GFF) (SUCRA 84.7%). Dupilumab (SUCRA 66.9%) ranked the fourth among all interventions but ranked the first among all the mAbs. Importantly, all mAbs demonstrated a good safety profile compared with placebo.ConclusionConsidering the improvement in FEV1 and its safety, the development of mAbs for COPD still holds significant clinical potential.Systematic review registrationPROSPERO, CRD42023452714

    (3E,5E)-3,5-Bis(4-hy­droxy-3,5-di­methoxy­benzyl­idene)oxan-4-one monohydrate

    Get PDF
    In the title compound, C23H24O8·H2O, the six-membered ring of the oxan-4-one (tetra­hydro­pyran-4-one) ring displays an envelope conformation with the heterocyclic O atom at the flap position. The dihedral angles between the terminal benzene rings is 37.23 (10)°. Classical intermolecular O—H⋯O and weak C—H⋯O hydrogen bonds are present in the crystal structure
    corecore